International Journal of Research in Pharmacy and Pharmaceutical Sciences

International Journal of Research in Pharmacy and Pharmaceutical Sciences


International Journal of Research in Pharmacy and Pharmaceutical Sciences
International Journal of Research in Pharmacy and Pharmaceutical Sciences
Vol. 4, Issue 3 (2019)

Relation of atenolol with development of myocardial infarction in hypertensive patients


Nusieba A Mohammed Ibrahim, Ali A M Sulieman

Atenolol is one of the β-adrenergic receptor antagonists. It is widely used for the treatment of hypertension as a selective antihypertensive drug. However, long-term use of atenolol may cause myocardial infarction (MI). To prove the relationship between atenolol and myocardial infarction, measurement of creatine phosphokinase-MB (CPK-MB) enzyme as a diagnostic indicator in early and long-term usage of this medication by hypertensive patients is recommended. This study was conducted in Al-Thoura Teaching Hospital, Emergency Department, El-beida, Libya, on 30 hypertensive patients using atenolol. They were divided into two groups (A and B) according to the duration of the drug usage. Group A consisted of 15 patients with a mean age (56±6) years. They used atenolol for a period of 1-5 years. Group B also consisted of 15 patients with a mean age (60±6) years. They used atenolol for a period of 6-20 years. Both groups were with nearly the same number of males and females. Venous blood samples were taken in the first 8 hrs. after onset symptoms of cardiac attack from each patient and the levels of CPK-MB were estimated and compared between the two groups. There was a significant correlation between levels of serum CPK-MB of group A and group B (P<0.05). Atenolol caused an increased level of serum CPK-MB, and this increase was directly proportional to the duration of the drug usage. CPK-MB is one of the cardiac markers that is released from the heart muscle when it is damaged as a result of myocardial infarction. Thus, atenolol has a significant correlation with the development of myocardial infarction.
Pages : 49-51